Medical - Devices
Compare Stocks
5 / 10Stock Comparison
SNWV vs ANIK vs NVCR vs LNTH vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Drug Manufacturers - Specialty & Generic
Medical - Instruments & Supplies
SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies |
| Market Cap | $143M | $203M | $1.92B | $5.92B | $16.97B |
| Revenue (TTM) | $41M | $116M | $674M | $1.55B | $4.13B |
| Net Income (TTM) | $-7M | $-11M | $-173M | $279M | $544M |
| Gross Margin | 77.7% | 58.6% | 75.2% | 60.5% | 52.8% |
| Operating Margin | 16.6% | -10.5% | -27.2% | 18.8% | 17.5% |
| Forward P/E | 17.4x | — | — | 17.5x | 17.2x |
| Total Debt | $25M | $24M | $290M | $738K | $2.63B |
| Cash & Equiv. | $10M | $57M | $103M | $359M | $1.96B |
SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SANUWAVE Health, In… (SNWV) | 100 | 16.1 | -83.9% |
| Anika Therapeutics,… (ANIK) | 100 | 45.2 | -54.8% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Lantheus Holdings, … (LNTH) | 100 | 662.8 | +562.8% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNWV vs ANIK vs NVCR vs LNTH vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SNWV ranks third and is worth considering specifically for growth exposure.
- Rev growth 60.0%, EPS growth 42.3%, 3Y rev CAGR 35.9%
- 60.0% revenue growth vs ANIK's -5.9%
ANIK lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
LNTH is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 41.9% 10Y total return vs HOLX's 124.3%
- 18.0% margin vs NVCR's -25.7%
- 12.4% ROA vs SNWV's -21.7%, ROIC 30.6% vs 159.8%
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 60.0% revenue growth vs ANIK's -5.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 18.0% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.41 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +37.1% vs SNWV's -47.4% | |
| Efficiency (ROA) | 12.4% ROA vs SNWV's -21.7%, ROIC 30.6% vs 159.8% |
SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SNWV leads in 1 of 6 categories
ANIK leads 1 • LNTH leads 1 • HOLX leads 1 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SNWV leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 100.0x SNWV's $41M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, SNWV holds the edge at +22.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $41M | $116M | $674M | $1.5B | $4.1B |
| EBITDAEarnings before interest/tax | $8M | -$7M | -$165M | $347M | $974M |
| Net IncomeAfter-tax profit | -$7M | -$11M | -$173M | $279M | $544M |
| Free Cash FlowCash after capex | -$784,000 | $1M | -$48M | $372M | $1000M |
| Gross MarginGross profit ÷ Revenue | +77.7% | +58.6% | +75.2% | +60.5% | +52.8% |
| Operating MarginEBIT ÷ Revenue | +16.6% | -10.5% | -27.2% | +18.8% | +17.5% |
| Net MarginNet income ÷ Revenue | -17.1% | -9.5% | -25.7% | +18.0% | +13.2% |
| FCF MarginFCF ÷ Revenue | -1.9% | +0.9% | -7.1% | +24.0% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.3% | +13.2% | +12.3% | +1.2% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +117.4% | -8.8% | -100.0% | +76.5% | -9.2% |
Valuation Metrics
ANIK leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 26.7x trailing earnings, LNTH trades at a 13% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, LNTH's 14.6x EV/EBITDA is more attractive than SNWV's 24.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $143M | $203M | $1.9B | $5.9B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $158M | $170M | $2.1B | $5.6B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -2.37x | -19.92x | -13.80x | 26.69x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.43x | — | — | 17.52x | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 24.09x | — | — | 14.61x | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 4.38x | 1.80x | 2.92x | 3.84x | 4.14x |
| Price / BookPrice ÷ Book value/share | — | 1.51x | 5.51x | 5.72x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 72.67x | 46.51x | — | 16.73x | 18.44x |
Profitability & Efficiency
LNTH leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-51 for NVCR. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), SNWV scores 7/9 vs LNTH's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -7.7% | -50.8% | +24.3% | +11.0% |
| ROA (TTM)Return on assets | -21.7% | -5.9% | -16.5% | +12.4% | +6.1% |
| ROICReturn on invested capital | +159.8% | -7.1% | -16.4% | +30.6% | +9.4% |
| ROCEReturn on capital employed | — | -6.4% | -28.9% | +17.1% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 5 | 5 | 7 |
| Debt / EquityFinancial leverage | — | 0.17x | 0.85x | 0.00x | 0.52x |
| Net DebtTotal debt minus cash | $15M | -$33M | $187M | -$358M | $667M |
| Cash & Equiv.Liquid assets | $10M | $57M | $103M | $359M | $2.0B |
| Total DebtShort + long-term debt | $25M | $24M | $290M | $738,000 | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 0.13x | — | -96.80x | 11.72x | 8.00x |
Total Returns (Dividends Reinvested)
Evenly matched — SNWV and LNTH each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs SNWV's -47.4%. The 3-year compound annual growth rate (CAGR) favors SNWV at 28.8% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -42.4% | +61.9% | +28.3% | +35.3% | +1.9% |
| 1-Year ReturnPast 12 months | -47.4% | +4.5% | +1.1% | +13.1% | +37.1% |
| 3-Year ReturnCumulative with dividends | +113.5% | -41.7% | -75.7% | -4.0% | -8.5% |
| 5-Year ReturnCumulative with dividends | -72.2% | -63.9% | -91.3% | +314.2% | +15.8% |
| 10-Year ReturnCumulative with dividends | -20.7% | -65.9% | +30.3% | +4192.5% | +124.3% |
| CAGR (3Y)Annualised 3-year return | +28.8% | -16.5% | -37.6% | -1.4% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs SNWV's 35.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.14x | 2.20x | 0.47x | 0.41x |
| 52-Week HighHighest price in past year | $46.59 | $16.24 | $20.06 | $93.00 | $76.04 |
| 52-Week LowLowest price in past year | $15.36 | $7.87 | $9.82 | $47.25 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +35.7% | +93.2% | +83.9% | +97.8% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 53.3 | 69.8 | 61.2 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 84K | 135K | 1.5M | 886K | 10.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SNWV as "Buy", ANIK as "Buy", NVCR as "Buy", LNTH as "Buy", HOLX as "Hold". Consensus price targets imply 224.3% upside for SNWV (target: $54) vs 3.9% for HOLX (target: $79).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $54.00 | — | $33.50 | $101.00 | $79.00 |
| # AnalystsCovering analysts | 2 | 6 | 15 | 17 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.7% | 0.0% | +5.1% | +4.4% |
SNWV leads in 1 of 6 categories (Income & Cash Flow). ANIK leads in 1 (Valuation Metrics). 1 tied.
SNWV vs ANIK vs NVCR vs LNTH vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SNWV or ANIK or NVCR or LNTH or HOLX a better buy right now?
For growth investors, SANUWAVE Health, Inc.
(SNWV) is the stronger pick with 60. 0% revenue growth year-over-year, versus -5. 9% for Anika Therapeutics, Inc. (ANIK). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate SANUWAVE Health, Inc. (SNWV) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNWV or ANIK or NVCR or LNTH or HOLX?
On trailing P/E, Lantheus Holdings, Inc.
(LNTH) is the cheapest at 26. 7x versus Hologic, Inc. at 30. 5x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SNWV or ANIK or NVCR or LNTH or HOLX?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus ANIK's -65. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNWV or ANIK or NVCR or LNTH or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — SNWV or ANIK or NVCR or LNTH or HOLX?
By revenue growth (latest reported year), SANUWAVE Health, Inc.
(SNWV) is pulling ahead at 60. 0% versus -5. 9% for Anika Therapeutics, Inc. (ANIK). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, SNWV leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SNWV or ANIK or NVCR or LNTH or HOLX?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus -96. 1% for SANUWAVE Health, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — SNWV leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SNWV or ANIK or NVCR or LNTH or HOLX more undervalued right now?
On forward earnings alone, Hologic, Inc.
(HOLX) trades at 17. 2x forward P/E versus 17. 5x for Lantheus Holdings, Inc. — 0. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNWV: 224. 3% to $54. 00.
08Which pays a better dividend — SNWV or ANIK or NVCR or LNTH or HOLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SNWV or ANIK or NVCR or LNTH or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SNWV and ANIK and NVCR and LNTH and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SNWV is a small-cap high-growth stock; ANIK is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.